In one small scale clinical trial of depressed patients, an improvement of symptoms which included anxiety, lack of drive and desire was observed.  In patients with dysthymia , unipolar , and bipolar depression significant improvement was observed.  In this series of studies, mesterolone lead to a significant decrease in luteinizing hormone and testosterone levels.  In another study, 100 mg mesterolone cipionate was administered twice monthly.  With regards to plasma testosterone levels, there was no difference between the treated versus untreated group, and baseline luteinizing hormone levels were minimally affected. 
In one randomized, double-blind 4-week trial, 38 dysthymic men were administered 75mg daily. Itil & Colleagues reported an improvement of symptoms which included anxiety, lack of drive and desire. Next, they administered a high dose (450mg/day) or placebo in a 6-week randomized trial of 52 men with a mean age of 40 years, suffering from dysthymia , unipolar and bipolar depression . Both the mesterolone and placebo groups improved significantly and there were no statistically significant differences between the two groups. In this series of studies mesterolone lead to a significant decrease in LH and testosterone levels. This is probably as a result of the extremely high dose used. In another, 100mg mesterolone cipionate was administered twice monthly. With regards to plasma T levels, there was no difference between the treated vs untreated group, and baseline LH levels were minimally affected.